Assessment of the clinical effect of topical tacalcitol on ichthyoses with retentive hyperkeratosis.

Abstract

BACKGROUND:

Topical tacalcitol (1alpha,24-dihydroxyvitamin D3) has been demonstrated to produce beneficial clinical effects on epidermo-hyperproliferative disorders such as psoriasis and pityriasis rubra pilaris. However, the efficacy of the agent has not been elucidated in retentive hyperkeratotic disorders.

OBJECTIVE:

The object of the study was to assess the clinical efficacy of topical tacalcitol against ichthyoses with retentive hyperkeratosis; X-linked ichthyosis (XLI), ichthyosis vulgaris (IV), and acquired ichthyosis (AI).

METHODS:

Tacalcitol was topically applied on 9 patients with the retention ichthyoses, using a single-blinded, bilaterally paired approach with right-left comparison of tacalcitol and the base.

RESULTS:

Clinical improvement obtained by topical tacalcitol exclusively was not superior to that of the vehicle alone in any of the ichthyotic patients.

CONCLUSION:

Topical tacalcitol therapy was ineffective against ichthyoses without epidermal hyperproliferation.

• Authors: M Okano
• Journal: Dermatology (Basel, Switzerland) (Dermatology) Vol. 202 Issue 2 Pg. 116-8 ( 2001) ISSN: 1018-8665 [Print] Switzerland
• PMID: 11306831 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
• Copyright: Copyright 2001 S. Karger AG, Basel.

Chemical References

• Anti-Inflammatory Agents
• Dermatologic Agents
• Dihydroxycholecalciferols
• 1 alpha,24-dihydroxyvitamin D3

Topics

• Administration, Topical
• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anti-Inflammatory Agents (therapeutic use)
• Child
• Dermatologic Agents (administration & dosage)
• Dihydroxycholecalciferols (administration & dosage)
• Female
• Humans
• Ichthyosis (complications, drug therapy, pathology)
• Ichthyosis Vulgaris (pathology)
• Ichthyosis, X-Linked (pathology)
• Keratosis (complications)
• Male
• Middle Aged